Last updated: 11/07/2018 05:37:47
Randomised study comparing the effects of inhaled Fluticasone Furoate (FF)/Vilanterol (VI; GW642444M) combination and FF on an allergen induced asthmatic response
EudraCT ID
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A randomised, double-blind, placebo-controlled, three-way crossover, repeat dose pilot study comparing the effect of inhaled fluticasone furoate/GW642444M combination and fluticasone furoate on the allergen-induced early asthmatic response in subjects with mild asthma
Trial description: We propose to use an inhaled allergen challenge model to explore the individual contributions of the components of a novel long-acting beta agonist (LABA)/ inhaled corticosteroid (ICS) combination product on protection from allergic triggers in asthma.
Primary purpose:
Treatment
Trial design:
Crossover Assignment
Masking:
Double (Participant, Investigator)
Allocation:
Randomized
Primary outcomes:
Weighted mean change from Baseline in forced expiratory volume in one second (FEV1) between 0–2 hours, following the 22–23 hour post-treatment allergen challenge on Day 29 of each treatment period
Timeframe: Baseline and Day 29 of each treatment period (up to Study Day 197)
Secondary outcomes:
Maximum percent decrease from Baseline in FEV1 between 0 2 hour, following the 22–23 hour post-treatment allergen challenge on Day 29 of each treatment period
Timeframe: Baseline and Day 29 of each treatment period (up to Study Day 197)
Minimum FEV1 absolute change from Baseline between 0–2 hour, following the 22–23 hour post-treatment allergen challenge on Day 29 of each treatment period
Timeframe: Baseline and Day 29 of each treatment period (up to Study Day 197)
Number of participants with treatment-emergent adverse events (AEs)
Timeframe: From the start of study medication until Follow-up/Early Withdrawal (up to 197 days)
Interventions:
Enrollment:
52
Primary completion date:
2010-12-10
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Oliver A, Ayer J, Quinn D, Goldfrad C, van Hecke B, Boyce M . Does combined fluticasone furoate / vilanterol reduce the fall in lung function following inhaled allergen 23h after dosing in adult asthma? A randomised, controlled trial. [Clin Transl Allergy]. 2012;2:11.
Oliver A, Ayer J, Quinn D, Goldfrad C, van Hecke B, Boyce M. Does combined fluticasone furoate / vilanterol reduce the fall in lung function following inhaled allergen 23h after dosing in adult asthma? A randomised, controlled trial. Clin Transl Allergy.2012;2(1):11.
Medical condition
Asthma
Product
fluticasone furoate, fluticasone furoate/vilanterol, vilanterol
Collaborators
GSK
Study date(s)
January 2010 to October 2010
Type
Interventional
Phase
2
Participation criteria
Sex
Female & Male
Age
18 - 65 years
Accepts healthy volunteers
No
- Body mass index within the range 18.5-35.0 kilograms/metre2 (kg/m2).
- Females of non-child bearing potential.
- Current or chronic history of liver disease, or known hepatic or biliary abnormalities
- Subject is hypertensive at screening
Inclusion and exclusion criteria
Inclusion criteria:
- Body mass index within the range 18.5-35.0 kilograms/metre2 (kg/m2).
- Females of non-child bearing potential.
- Documented history of bronchial asthma, first diagnosed at least 6 months prior to the screening visit and currently being treated only with intermittent short-acting beta -agonist therapy by inhalation
- Pre-bronchodilator FEV1 >70% of predicted at screening
- Subjects who are current non-smokers
- Methacholine challenge PC20 < 8 mg/mL at screening
- Screening allergen challenge demonstrates that the subject experiences an early asthmatic response
Exclusion criteria:
- Current or chronic history of liver disease, or known hepatic or biliary abnormalities
- Subject is hypertensive at screening
- Respiratory tract infection and/or exacerbation of asthma within 4 weeks prior to the first dose of study medication.
- History of life-threatening asthma
- Symptomatic with hay fever at screening or predicted to have symptomatic hayfever
- Unable to abstain from short acting beta agonists
- Unable to abstain from antihistamines
- Unable to abstain from other medications including non-steroidal anti-inflammatory drugs (NSAIDs), anti-depressant drugs, anti-asthma anti-rhinitis or hay fever medication
- The subject has participated in a study with a new molecular entity during the previous 3 months or has participated in 4 or more clinical studies in the previous 12 months
- undergoing allergen desensitisation therapy
Trial location(s)
Location
GSK Investigational Site
Manchester, United Kingdom, M23 9QZ
Status
Will Be Recruiting
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Study complete
Actual primary completion date
2010-12-10
Actual study completion date
2010-12-10
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Participate in clinical trial
Additional information
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Click hereAccess to clinical trial data by researchers
Visit website